FDA Approves New Treatment for ALK+ NSCLC Patients

2018-11-05T14:35:44+00:00November 2nd, 2018|Hot Topics, News|0 Comments

Friday, November 2, 2018 – Today the Food and Drug Administration (FDA) granted accelerated approval to lorlatinib (LORBRENA) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Click here to learn more. 

Leave A Comment

No announcement available or all announcement expired.